Senior Director, External Communications
Invivyda month ago
Highlight
HybridFull-timeDirector
Summary
Invivyd, Inc. is seeking a Senior Director, External Communications to join their team in Hybrid, New Haven, CT. The role involves leading strategy and execution of external communications programs that advance the Invivyd brand and support business objectives.
About the Role
As the Senior Director, External Communications, you will be responsible for developing and executing external communications strategies, overseeing media relations, corporate messaging, and stakeholder communications. You will collaborate with various functions and external partners to position Invivyd as a thought leader in the biotechnology sector, translating complex scientific information into accessible narratives, and managing external communications risks.
About You
Required:
- Bachelor's degree required; Advanced degree in communications, journalism, life sciences, or a related field preferred.
- At least 10 years of progressive experience in external communications, corporate communications or public affairs, ideally in the biotech, life sciences or pharmaceutical sector.
- Exceptional written and verbal communication skills.
- Proven track record leading media relations and corporate communications at a senior level.
- Deep understanding of the biotech landscape, including clinical development and regulatory processes.
Preferred:
- Experience in communications in support of regulatory approvals and successful drug launches.
- Experience managing issues and crisis communications in a highly regulated environment.
- Demonstrated track record building and executing external communications strategies that support business growth and corporate reputation.
- Ability to thrive in a fast-paced, high-growth, science-driven environment.
Invivyd
Invivyd, Inc. (Nasdaq: IVVD) creates medicines that are more potent and resistant to virus evolution than the human immune system. We deploy a proprietary integrated technology platform unique in the industry to assess, monitor, drug and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more. #covid19 #immunocompromised
New Haven, CT